Cyclo3pss Corporation (CYPS) Peer Comparison
$0.00
$0.00 (0.00%)As on 31-Aug-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 12,753 | 12,153 | 10,906 | 9,948 |
Revenue ($ Mln) |
-- | 1,505 | 6,164 | 613 | 785 |
Net Profit ($ Mln) |
-- | 160.59 | 625.00 | -188.05 | 41.54 |
Net Margin (%) |
-- | 10.67 | 5.41 | -30.68 | 5.29 |
RoE (%) |
-- | 10.86 | 11.84 | -28.10 | 1.97 |
Price to Earnings |
-- | 79.35 | 19.89 | -- | 251.81 |
Price-To-Book |
-- | 8.41 | 2.37 | 16.38 | 4.86 |
Income Statement ($ Mln)
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
-- | -- | 1,787.71 | -- | 7.77 |
|
Cost of Revenue
|
-- | -- | 531.63 | -- | 3.48 |
|
Gross Profit
|
-- | -- | 1,256.08 | -- | 4.29 |
|
Operating Expenses
|
-- | -- | 1,516.79 | -- | 9.39 |
|
Operating Profit (EBIT)
|
-- | -- | 242.73 | -- | -5.09 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-- | -- | 290.73 | -- | -4.54 |
|
Provision for Tax
|
-- | -- | 105.98 | -- | 4.54 |
|
Profit after Tax (Net Income)
|
-- | -- | 184.75 | -- | -4.54 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-0.85 | -- | 180.43 | -- | -- |
Liabilities ($ Mln)
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-- | -- | 833.21 | -- | 30.34 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
-- | -- | 651.04 | -- | 0.09 |
|
Current Liabilities
|
1.13 | -- | 508.82 | -- | 2.81 |
|
Total Liabilities
|
-- | -- | 1,993.07 | -- | 33.15 |
Assets ($ Mln)
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
-- | -- | 1,135.06 | -- | 19.33 |
|
Current Assets
|
0.15 | -- | 858.02 | -- | 13.82 |
|
Total Assets
|
-- | -- | 1,993.07 | -- | 33.15 |
|
Total Debt*
|
-- | -- | 509.40 | -- | 0.09 |
|
Net Current Assets
|
-- | -- | -- | -- | -- |
Cashflow ($ Mln)
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.62 | -- | 242.85 | -- | -5.26 |
|
Cash Flow from Investing Activities
|
0.11 | -- | -346.31 | -- | 2.67 |
|
Cash from Financing Activities
|
0.52 | -- | 19.01 | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-- | -- | 15.79 | -- | -16.50 |
|
ROE (%)
|
-- | -- | 25.98 | -- | -16.53 |
|
ROA (%)
|
-- | -- | 10.29 | -- | -14.57 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -- | 10.33 | -- | -58.38 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | 0.13 | -- | 0.81 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-- | -- | -2.11 | -- | -1.71 |
|
EPS Growth (%)
|
-- | -- | -0.03 | -- | 0.01 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -- | 155.46 | -- | -18.30 |
|
Price / Book Value
|
-- | -- | 34.47 | -- | 2.74 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | -- | 80.55 | -- | -8.26 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -- | 0.61 | -- | 0.00 |
|
Short term debt to equity ratio
|
-- | -- | 0.29 | -- | -- |
|
Current Ratio
|
0.14 | -- | 1.69 | -- | 4.92 |
|
Quick Ratio
|
-- | -- | 0.96 | -- | 4.56 |
|
Interest Coverage
|
-- | -- | 10.28 | -- | -2.09 |
Operating Efficiency Ratios
| Cyclo3pss Corporation (CYPS) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | 0.00 | -- | 10.16 |
|
Asset Turnover
|
-- | -- | 1.00 | -- | 0.25 |
|
Receivable days
|
-- | -- | 39.16 | -- | 39.88 |
|
Inventory Days
|
-- | -- | 243.14 | -- | 101.27 |
|
Payable days
|
-- | -- | 150.86 | -- | 89.42 |
|
Cash Conversion Cycle
|
-- | -- | 131.43 | -- | 51.73 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
